OKYO Pharma Ltd

Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain London and New York, NY, September 9, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior […] The post OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 appeared first on OKYO Pharma.

London and New York, NY, September 8, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026. Details of the event are as follows: Presenters: […] The post OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference appeared first on OKYO Pharma.

London and New York, NY, July 28, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of […] The post OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer appeared first on OKYO Pharma.

London and New York, NY, July 27, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026. Company Participation: Robert J. Dempsey, […] The post OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 appeared first on OKYO Pharma.

London and New York, NY, July 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per […] The post OKYO Pharma Announces Purchase of Shares by Director appeared first on OKYO Pharma.

London and New York, NY, July 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company’s ordinary shares on NASDAQ at […] The post OKYO Pharma Announces Purchase of Shares by Chief Executive Officer appeared first on OKYO Pharma.

London and New York, NY, July 22, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has […] The post OKYO Pharma Announces Purchase of Shares by Chairman appeared first on OKYO Pharma.

London and New York, NY, July 22, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase […] The post OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director appeared first on OKYO Pharma.

London and New York, NY, July 22, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ […] The post OKYO Pharma Announces Purchase of Shares by Chief Medical Officer appeared first on OKYO Pharma.

London and New York, NY, July 21, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026. Details of […] The post OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference appeared first on OKYO Pharma.